Overall Survival of Hungarian Cancer Patients Diagnosed Between 2011 and 2019, Based on the Health Insurance Fund Database.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kiss Zoltán, Berki Tamás László, Maráz Anikó, Horváth Zsolt, Nagy Péter, Fábián Ibolya, Kovács Valéria, Rokszin György, Surján György, Barcza Zsófia, Kenessey István, Wéber András, Wittmann István, Molnár Gergő Attila, Szabó Tamás G, Buga Viktória, Karamousouli Eugenia, Darida Miklós, Abonyi-Tóth Zsolt, Bertókné Tamás Renáta, Fürtős Viktória Diána, Bogos Krisztina, Moldvay Judit, Gálffy Gabriella, Tamási Lilla, Müller Veronika, Krasznai Zoárd Tibor, Ostoros Gyula, Pápai-Székely Zsolt, Branyiczkiné Géczy Gabriella, Hilbert Lászlóné, Polgár Csaba, Vokó Zoltán
Аннотация
Background: Assessing cancer survival trends is crucial for monitoring progress in cancer management and prevention. As part of the broader HUN-CANCER EPI study, this analysis examined overall survival (OS) in the Hungarian cancer population between 2011 and 2019. Methods: Using data extracted from the Hungarian National Health Insurance Fund (NHIF) database, short- and long-term OS were estimated for various cancer types according to age, sex, and diagnostic period using Kaplan-Meier analysis. The study also identified cancer types with significant early mortality following diagnosis. Results: From 2011 to 2019, a total of 528,808 patients were diagnosed with cancer. During the 2015-2019 diagnostic period, the lowest 5-year OS rates were observed for esophageal (7.0%), pancreatic (10.7%), liver (12.5%), gallbladder (13.9%), and lung cancer (18.4%). Conversely, tumor types with better OS included testicular cancer (91.6%), thyroid cancer (89.0%), Hodgkin's lymphoma (84.0%), melanoma (78.6%), and breast cancer (74.1%). A notable proportion of deaths occurred within 2 months of diagnosis for liver (33.2%), pancreatic (27.9%), and gallbladder cancer (29.0%). Significant early mortality within 6 months post-diagnosis was also noted for esophageal (51.3%), stomach (42.9%), and lung cancer (41.7%). Conclusions: The HUN-CANCER EPI study conducted between 2011 and 2019 provides valuable insights into cancer survival patterns in Hungary, emphasizing the importance of early detection and targeted interventions to improve patient outcomes.